Abstract：
UNASSIGNED: Lung transplantation is the gold standard for the treatment of end stage lung disease but is limited by donor availability. Recently, the donor pool has seen significant expansion with liberalization of donor criteria. However, extended criteria donors can require additional time to prepare for implantation, necessitating additional preservation time of donor lungs.
UNASSIGNED: We present a review of current lung transplant storage strategies including new methodologies and technological advancements. The current standard, static cold storage, is a simple and cost-effective method of preserving grafts, but offers little flexibility with limited ability to mitigate ischemic-reperfusion injury, inflammation, and hypothermic tissue damage. Novel ex vivo lung perfusion (EVLP) devices, TransMedics OCS and XVIVO perfusion systems, extend preservation time by perfusing, and ventilating donor lungs while simultaneously allowing for evaluation of lung viability. Perfusate, preservation solutions, additives, temperature regulation, and assessment of organ damage are all critical components when evaluating the success and outcomes of these devices.
UNASSIGNED: EVLP devices are more costly and often require additional resources and personnel support compared to static cold storage, but may provide the opportunity to extend preservation time, perform functional assessment, mitigate ischemic injury, and optimize extended criteria donors.
UNASSIGNED: We present a review of current lung transplant storage strategies including new methodologies and technological advancements. The current standard, static cold storage, is a simple and cost-effective method of preserving grafts, but offers little flexibility with limited ability to mitigate ischemic-reperfusion injury, inflammation, and hypothermic tissue damage. Novel ex vivo lung perfusion (EVLP) devices, TransMedics OCS and XVIVO perfusion systems, extend preservation time by perfusing, and ventilating donor lungs while simultaneously allowing for evaluation of lung viability. Perfusate, preservation solutions, additives, temperature regulation, and assessment of organ damage are all critical components when evaluating the success and outcomes of these devices.
UNASSIGNED: EVLP devices are more costly and often require additional resources and personnel support compared to static cold storage, but may provide the opportunity to extend preservation time, perform functional assessment, mitigate ischemic injury, and optimize extended criteria donors.
摘要：
未经证实：肺移植是治疗终末期肺病的金标准，但受供体可获得性的限制。最近,随着捐助者标准的放宽，捐助者池已经大大扩大。然而,延长标准供体可能需要额外的时间来准备植入，需要供体肺的额外保存时间。
UNASSIGNED：我们对目前的肺移植储存策略进行了综述，包括新的方法和技术进步。现行标准,静态冷库，是一种简单且经济有效的保存移植物的方法，但在减轻缺血再灌注损伤的能力有限的情况下，灵活性很小，炎症,和低温组织损伤。新型离体肺灌注（EVLP）装置，TransMedicsOCS和XVIVO灌注系统，通过灌注延长保存时间，和通气供体肺，同时允许评估肺活力。灌注液,保存解决方案，添加剂,温度调节,和评估器官损伤都是评估这些设备的成功和结果的关键组成部分。
UNASSIGNED：与静态冷存储相比，EVLP设备成本更高，并且通常需要额外的资源和人员支持，但可能提供延长保存时间的机会，执行功能评估，减轻缺血性损伤，并优化扩展标准捐助者。
UNASSIGNED：我们对目前的肺移植储存策略进行了综述，包括新的方法和技术进步。现行标准,静态冷库，是一种简单且经济有效的保存移植物的方法，但在减轻缺血再灌注损伤的能力有限的情况下，灵活性很小，炎症,和低温组织损伤。新型离体肺灌注（EVLP）装置，TransMedicsOCS和XVIVO灌注系统，通过灌注延长保存时间，和通气供体肺，同时允许评估肺活力。灌注液,保存解决方案，添加剂,温度调节,和评估器官损伤都是评估这些设备的成功和结果的关键组成部分。
UNASSIGNED：与静态冷存储相比，EVLP设备成本更高，并且通常需要额外的资源和人员支持，但可能提供延长保存时间的机会，执行功能评估，减轻缺血性损伤，并优化扩展标准捐助者。
